Nigrostriatal Dopamine Terminals In Parkinson'S Disease plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Nigrostriatal terminals are the axon terminals of substantia nigra pars compacta (SNpc) dopaminergic neurons that project to the striatum (caudate and putamen). These terminals are the primary site of neurodegeneration in Parkinson's disease (PD). [1]
DaTscan — Dopamine transporter imaging
Nigrostriatal Dopamine Terminals In Parkinson'S Disease plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications. [2]
The study of Nigrostriatal Dopamine Terminals In Parkinson'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [3]
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [4]
Caudron et al. Nigrostriatal terminal degeneration (2023). 2023. ↩︎
Barker et al. Cell therapy for PD (2020). 2020. ↩︎
Kalia & Lang, PD neuroprotection strategies (2024). 2024. ↩︎